Chronic myeloid leukemia following chemotherapy with 5′-deoxy-5-fluorouridine for gastric cancer

  • Motohiro Tsuzuki
  • , Kousuke Handa
  • , Kiyoko Yamamoto
  • , Akio Hasegawa
  • , Yukiya Yamamoto
  • , Masato Watanabe
  • , Syuichi Mizuta
  • , Fumio Maruyama
  • , Masataka Okamoto
  • , Nobuhiko Emi
  • , Kohji Ezaki

Research output: Contribution to journalArticlepeer-review

Abstract

We report here a very rare case of chronic myeloid leukemia (CML) following long-term chemotherapy with 5′-deoxy-5-fluorouridine (5′-DFUR) for gastric cancer. A 69-year-old man was diagnosed with the chronic phase of CML. Six years previously, he underwent radical subtotal gastrectomy for gastric cancer, and was subsequently treated with oral anti-metabolite 5′-DFUR as adjuvant chemotherapy for 6 years. He was placed on imatinib therapy, and achieved a major molecular response 10 months after the initiation of therapy. This is the first reported case of therapy-related CML following 5′-DFUR treatment.

Original languageEnglish
Pages (from-to)1739-1741
Number of pages3
JournalInternal Medicine
Volume47
Issue number19
DOIs
Publication statusPublished - 2008
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Fingerprint

Dive into the research topics of 'Chronic myeloid leukemia following chemotherapy with 5′-deoxy-5-fluorouridine for gastric cancer'. Together they form a unique fingerprint.

Cite this